Amgen annual operating cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Amgen Operating Cash Flow Growth & History (AMGN)
Amgen's operating cash flow was $9.96B for fiscal 2025.
View full Amgen company overviewAmgen annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.96B | −$1.53B | −13.33% |
| 2024 | 2024-12-31 | $11.49B | $3.02B | +35.64% |
| 2023 | 2023-12-31 | $8.47B | −$1.25B | −12.86% |
| 2022 | 2022-12-31 | $9.72B | $460.0M | +4.97% |
| 2021 | 2021-12-31 | $9.26B | −$1.24B | −11.77% |
| 2020 | 2020-12-31 | $10.50B | $1.35B | +14.72% |
| 2019 | 2019-12-31 | $9.15B | −$2.15B | −19.00% |
| 2018 | 2018-12-31 | $11.30B | $119.0M | +1.06% |
| 2017 | 2017-12-31 | $11.18B | $823.0M | +7.95% |
| 2016 | 2016-12-31 | $10.35B | $623.0M | +6.40% |
| 2015 | 2015-12-31 | $9.73B | $779.0M | +8.70% |
| 2014 | 2014-12-31 | $8.95B | $2.66B | +42.30% |
| 2013 | 2013-12-31 | $6.29B | $409.0M | +6.95% |
| 2012 | 2012-12-31 | $5.88B | $763.0M | +14.91% |
| 2011 | 2011-12-31 | $5.12B | −$668.0M | −11.54% |
| 2010 | 2010-12-31 | $5.79B | −$549.0M | −8.66% |
| 2009 | 2009-12-31 | $6.34B | $348.0M | +5.81% |
| 2008 | 2008-12-31 | $5.99B | $587.0M | +10.87% |
| 2007 | 2007-12-31 | $5.40B | — | — |
Amgen quarterly operating cash flow
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q1.12
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.00B | $1.72B | +75.53% |
| Q1 2026 | 2026-03-31 | $2.19B | $798.0M | +57.37% |
| Q4 2025 | 2025-12-31 | $1.60B | −$3.17B | −66.40% |
| Q3 2025 | 2025-09-30 | $4.68B | $1.11B | +31.17% |
| Q2 2025 | 2025-06-30 | $2.28B | −$179.0M | −7.28% |
| Q1 2025 | 2025-03-31 | $1.39B | $702.0M | +101.89% |
| Q4 2024 | 2024-12-31 | $4.77B | $4.23B | +786.80% |
| Q3 2024 | 2024-09-30 | $3.57B | $811.0M | +29.38% |
| Q2 2024 | 2024-06-30 | $2.46B | −$1.65B | −40.16% |
| Q1 2024 | 2024-03-31 | $689.0M | −$375.0M | −35.24% |
| Q4 2023 | 2023-12-31 | $538.0M | −$2.11B | −79.69% |
| Q3 2023 | 2023-09-30 | $2.76B | −$218.0M | −7.32% |
| Q2 2023 | 2023-06-30 | $4.11B | $2.18B | +112.90% |
| Q1 2023 | 2023-03-31 | $1.06B | −$1.10B | −50.83% |
| Q4 2022 | 2022-12-31 | $2.65B | −$159.0M | −5.66% |
| Q3 2022 | 2022-09-30 | $2.98B | $560.0M | +23.16% |
| Q2 2022 | 2022-06-30 | $1.93B | −$1.0M | −0.05% |
| Q1 2022 | 2022-03-31 | $2.16B | $60.0M | +2.85% |
| Q4 2021 | 2021-12-31 | $2.81B | $655.0M | +30.42% |
| Q3 2021 | 2021-09-30 | $2.42B | −$950.0M | −28.21% |
| Q2 2021 | 2021-06-30 | $1.93B | −$911.0M | −32.05% |
| Q1 2021 | 2021-03-31 | $2.10B | −$30.0M | −1.41% |
| Q4 2020 | 2020-12-31 | $2.15B | −$361.0M | −14.36% |
| Q3 2020 | 2020-09-30 | $3.37B | −$9.0M | −0.27% |
| Q2 2020 | 2020-06-30 | $2.84B | $1.43B | +100.99% |
| Q1 2020 | 2020-03-31 | $2.13B | $289.0M | +15.66% |
| Q4 2019 | 2019-12-31 | $2.51B | −$680.0M | −21.29% |
| Q3 2019 | 2019-09-30 | $3.38B | $104.0M | +3.18% |
| Q2 2019 | 2019-06-30 | $1.41B | −$688.0M | −32.73% |
| Q1 2019 | 2019-03-31 | $1.84B | −$882.0M | −32.34% |
| Q4 2018 | 2018-12-31 | $3.19B | $182.0M | +6.04% |
| Q3 2018 | 2018-09-30 | $3.27B | −$181.0M | −5.24% |
| Q2 2018 | 2018-06-30 | $2.10B | −$224.0M | −9.63% |
| Q1 2018 | 2018-03-31 | $2.73B | $342.0M | +14.34% |
| Q4 2017 | 2017-12-31 | $3.01B | — | — |
| Q3 2017 | 2017-09-30 | $3.45B | $792.0M | +29.75% |
| Q2 2017 | 2017-06-30 | $2.33B | −$351.0M | −13.11% |
| Q1 2017 | 2017-03-31 | $2.38B | $470.0M | +24.54% |
| Q3 2016 | 2016-09-30 | $2.66B | −$230.0M | −7.95% |
| Q2 2016 | 2016-06-30 | $2.68B | −$607.0M | −18.48% |
| Q1 2016 | 2016-03-31 | $1.92B | $433.0M | +29.22% |
| Q4 2015 | 2015-12-31 | $2.07B | — | — |
| Q3 2015 | 2015-09-30 | $2.89B | $151.0M | +5.51% |
| Q2 2015 | 2015-06-30 | $3.28B | $1.06B | +47.46% |
| Q1 2015 | 2015-03-31 | $1.48B | $340.0M | +29.77% |
| Q3 2014 · Sep 30 | 2014-09-30 | $2.74B | $934.0M | +51.69% |
| Q2 2014 | 2014-06-30 | $2.23B | $627.0M | +39.19% |
| Q1 2014 | 2014-03-31 | $1.14B | $93.0M | +8.87% |
| Q3 2013 · Sep 30 | 2013-09-30 | $1.81B | $84.0M | +4.88% |
| Q2 2013 · Jun 30 | 2013-06-30 | $1.60B | −$775.0M | −32.63% |
| Q1 2013 · Mar 31 | 2013-03-31 | $1.05B | $77.0M | +7.92% |
| Q3 2012 · Sep 30 | 2012-09-30 | $1.72B | $754.0M | +77.81% |
| Q2 2012 · Jun 30 | 2012-06-30 | $2.38B | $839.0M | +54.62% |
| Q1 2012 · Mar 31 | 2012-03-31 | $972.0M | −$58.0M | −5.63% |
| Q3 2011 | 2011-09-30 | $969.0M | −$333.0M | −25.58% |
| Q2 2011 | 2011-06-30 | $1.54B | −$28.0M | −1.79% |
| Q1 2011 | 2011-03-31 | $1.03B | $117.0M | +12.81% |
| Q4 2010 | 2010-12-31 | $2.01B | $185.0M | +10.15% |
| Q3 2010 | 2010-09-30 | $1.30B | −$673.0M | −34.08% |
| Q2 2010 | 2010-06-30 | $1.56B | −$115.0M | −6.85% |
| Q1 2010 | 2010-03-31 | $913.0M | $54.0M | +6.29% |
| Q4 2009 | 2009-12-31 | $1.82B | — | — |
| Q3 2009 | 2009-09-30 | $1.98B | $585.0M | +42.09% |
| Q2 2009 | 2009-06-30 | $1.68B | — | — |
| Q1 2009 | 2009-03-31 | $859.0M | — | — |
| Q3 2008 | 2008-09-30 | $1.39B | — | — |
Amgen operating cash flow trends
Over the last five fiscal years, Amgen's operating cash flow decreased from $10.50B to $9.96B, a change of −$539.0M. The latest reported quarter, Q2 2026, shows $4.00B.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amgen source filings ↗Community posts
Amgen–AstraZeneca combination cuts lung-cancer mortality risk by 58%
Amgen ($AMGN) disclosed detailed Phase 3 results showing that adding Imdelltra to AstraZeneca ($AZN)’s Imfinzi reduced the risk of death by 58% in first-line maintenance treatment of extensive-stage small-cell lung cancer. Median overall su ...
